When a medical device meant to protect your life gives you dangerously wrong information, the consequences can be catastrophic. The FreeStyle Libre 3 lawsuit glucose sensor defect has emerged as one of the most significant medical device liability cases of 2026, involving inaccurate continuous glucose monitor (CGM) readings that have led to incorrect insulin dosing, seizures, cardiac events, and confirmed deaths. If you or a loved one suffered harm after relying on a FreeStyle Libre 3 or Libre 3 Plus sensor, understanding how these cases are valued in litigation is the critical first step toward justice.
What Happened: The FreeStyle Libre 3 Recall and FDA Action in 2025–2026
Abbott Laboratories recalled approximately 3 million FreeStyle Libre 3 and Libre 3 Plus sensors in November 2025 after a manufacturing defect was identified that caused inaccurate glucose readings. For people managing diabetes — a condition where precise blood sugar monitoring can mean the difference between life and death — inaccurate readings from a trusted medical device represent a profound and dangerous betrayal.
The scale of reported harm has been staggering. According to data available as of January 7, 2026, the FDA’s medical device recall database reflects 860 serious injuries and 7 deaths globally linked to these defective sensors. These are not minor inconveniences — these are hospitalizations, seizures, hypoglycemic crises, cardiac events, and fatalities suffered by real patients who trusted that their device was accurately reporting their blood sugar levels.
The regulatory picture worsened in January 2026, when the FDA issued a formal warning letter to Abbott citing significant quality system violations. Investigators found that Abbott released devices without adequately testing accuracy after final assembly and sterilization — a fundamental failure in the manufacturing process for a life-critical medical device. This regulatory finding is enormously significant in litigation, as it establishes both defect and negligence at the manufacturer level.
| Data Point | Figure | Source / Date |
|---|---|---|
| Sensors recalled (November 2025) | ~3 million units | FDA Recall Database, November 2025 |
| Serious injuries reported globally | 860+ | FDA MDR Data, January 7, 2026 |
| Deaths reported globally | 7 | FDA MDR Data, January 7, 2026 |
| FDA enforcement action | Warning Letter issued | FDA, January 2026 |
| Class action filed | Alameda County, California | February 2026 |
| Minimum user age for affected devices | 2 years old | Abbott product labeling, 2026 |
Critically, the affected devices are cleared for use in patients as young as 2 years old, meaning children are among the potential victims of this defect. Parents who relied on these sensors to monitor their toddler’s or young child’s glucose levels may have administered insulin or withheld treatment based on completely false readings.
A Devastating Example: The Michael Leroy Ford Case
No case illustrates the lethal potential of this defect more clearly than the death of Michael Leroy Ford of Alameda, California, who died on November 17, 2025. According to allegations in litigation, Ford’s FreeStyle Libre 3 Plus sensor falsely displayed a glucose reading of 68 mg/dL — a level suggesting dangerous hypoglycemia (low blood sugar) requiring urgent treatment. In reality, his actual blood glucose was 551 mg/dL — a life-threatening hyperglycemic crisis requiring the exact opposite intervention.
This 483-point variance between the displayed and actual reading is not a rounding error. It is the kind of catastrophic inaccuracy that, when acted upon in good faith by a patient or caregiver, can cause a person to receive dangerous amounts of insulin when their body was already overwhelmed by excess glucose. The Ford case has become a focal point of the broader FreeStyle Libre 3 lawsuit glucose sensor defect litigation and underscores why these cases are being taken with the utmost seriousness by courts and attorneys in 2026.
If a loved one died in circumstances like this, a wrongful death calculator can help you begin to understand the financial dimensions of your potential claim, including lost income, loss of companionship, and survivor damages — though every case requires individualized legal evaluation.
How Personal Injury Damages Are Calculated in FreeStyle Libre 3 Cases
Litigation value in the FreeStyle Libre 3 lawsuit glucose sensor defect cases is determined by analyzing several overlapping categories of compensable harm. Unlike many product liability cases, these injuries occur on a spectrum — from a single ER visit to permanent disability or death — and the damages calculations reflect that range.
Economic Damages: The Measurable Financial Losses
Economic damages form the quantifiable foundation of any personal injury claim and typically include the following:
- Medical expenses: Emergency room visits, hospitalization, ICU care, ambulance transport, follow-up treatment, and ongoing care for complications like seizure-related injuries or cardiac damage.
- Lost wages: Income lost during recovery, including for family members who had to take time off to care for an injured child or adult.
- Future lost earning capacity: Where a patient suffers permanent neurological injury from a seizure or hypoxic brain injury from a cardiac event, future income losses must be projected and discounted to present value.
- Future medical care costs: Ongoing treatment, medication, rehabilitation, and in severe cases, long-term home care or assisted living expenses.
In cases involving severe injuries such as hypoxic brain injury resulting from a glucose-related cardiac arrest, the lifetime cost of care alone can reach into the millions of dollars. For survivors of serious neurological events, a brain injury calculator can provide an initial estimate of these long-term economic losses, though a qualified life care planner and economic expert will ultimately develop the formal damages model used in litigation.
Non-Economic Damages: Pain, Suffering, and Loss of Life Quality
Beyond the financial losses, courts and juries recognize that physical pain, emotional trauma, and the loss of the ability to enjoy daily life have real value in litigation. Non-economic damages in FreeStyle Libre 3 lawsuit glucose sensor defect cases may include:
- Pain and suffering during the injurious event (seizure, cardiac episode, hospitalization)
- Ongoing anxiety, PTSD, or fear associated with continued diabetes management after a near-fatal device failure
- Loss of consortium for spouses or domestic partners
- Loss of parental guidance and companionship in wrongful death cases involving parents of minor children
In states without caps on non-economic damages, serious and permanent injuries can command non-economic awards well in excess of economic losses. California — where the Ford case and the class action are centered — applies a $350,000 cap on non-economic damages in medical malpractice cases, but product liability claims against a manufacturer like Abbott are not subject to the same cap and are governed by separate standards under California Civil Code Section 3294, which also permits punitive damages where malice, oppression, or fraud is proven.
Punitive Damages: Holding Abbott Accountable Beyond Compensation
The FDA’s January 2026 warning letter finding that Abbott released devices without testing accuracy after final assembly and sterilization is the kind of evidence that plaintiffs’ attorneys will argue demonstrates conscious disregard for user safety. Punitive damages are designed not to compensate the plaintiff but to punish the defendant and deter future misconduct. In major product liability cases with documented regulatory violations, punitive damage multipliers can range from two to ten times the compensatory damages award, depending on the jurisdiction and the egregiousness of the conduct.
Individual Lawsuit vs. Class Action: Which Path Is Right for You?
One of the most important distinctions in the FreeStyle Libre 3 lawsuit glucose sensor defect litigation landscape is the difference between the class action filed in Alameda County, California in February 2026 and individual personal injury lawsuits pursued by seriously injured plaintiffs.
The Class Action: Economic Loss and Consumer Claims
The California class action filed in February 2026 primarily addresses consumer protection and economic claims — people who purchased defective sensors, who were denied the benefit of their bargain, or who suffered out-of-pocket costs related to the defect. Class actions are powerful tools for aggregating large numbers of similar, relatively small claims. However, class action settlements are divided among all class members, and individual class members typically receive modest payments.
Class membership may be appropriate if your harm was primarily economic — you purchased recalled sensors, incurred pharmacy costs replacing them, or paid for additional fingerstick testing to verify readings you no longer trusted. For more information on class action procedures, Rule 23 of the Federal Rules of Civil Procedure governs class certification standards at the federal level.
Individual Personal Injury Lawsuits: Where Serious Injuries Are Valued
If you or a family member suffered a serious physical injury — a seizure, a hypoglycemic or hyperglycemic crisis requiring hospitalization, a cardiac event, permanent neurological damage, or death — an individual personal injury lawsuit is almost certainly the more appropriate and financially significant path. Individual plaintiffs retain full control of their claims and can pursue the full range of compensatory and punitive damages without diluting the recovery across thousands of class members.
Individual cases also allow attorneys to develop case-specific evidence about the exact readings shown, the clinical response taken, and the specific medical outcome — evidence that is far more powerful before a jury than the generalized evidence presented in class proceedings. As of mid-2026, attorneys handling these cases report that serious individual injury claims are being aggressively pursued and that the FDA warning letter evidence significantly strengthens these cases.
Who Qualifies to File a FreeStyle Libre 3 Injury Lawsuit in 2026
If you are evaluating whether you have a viable claim in the FreeStyle Libre 3 lawsuit glucose sensor defect litigation, the following factors are central to case viability:
- You used a FreeStyle Libre 3 or Libre 3 Plus sensor that was subject to the November 2025 recall.
- You or a caregiver acted on a reading that was later determined or suspected to be inaccurate — administering insulin, consuming glucose, delaying emergency treatment, or making another clinical decision based on the displayed value.
- You suffered a physical injury — including but not limited to: hypoglycemic seizure, diabetic ketoacidosis (DKA), cardiac event, fall or accident during an episode, hospitalization, or death of a family member.
- A causal link exists between the inaccurate reading and the injury — ideally documented through medical records, EMS reports, hospital labs, or contemporaneous blood glucose checks.
- You are within the applicable statute of limitations for your state. Most states allow two to three years from the date of injury to file a personal injury claim, though tolling rules may apply in certain circumstances. Review your state’s statute of limitations through Justia’s product liability resources for jurisdiction-specific guidance.
Parents filing on behalf of children who were harmed should note that the statute of limitations for minors is typically tolled until the child reaches the age of majority, though this varies by state and you should seek legal guidance promptly to preserve evidence.
Frequently Asked Questions About FreeStyle Libre 3 Lawsuit Damages
FAQ 1: How much is a FreeStyle Libre 3 lawsuit worth if I had a seizure from a false reading?
The value of a seizure-related claim in the FreeStyle Libre 3 lawsuit glucose sensor defect litigation depends on the severity and permanence of the injury. A single seizure resulting in a brief hospitalization and full recovery might settle in the range of $75,000 to $250,000, accounting for medical bills, lost wages, and pain and suffering. A seizure causing a fall with a traumatic brain injury, prolonged hospitalization, or lasting neurological effects could be valued significantly higher — potentially in the seven-figure range — particularly where permanent impairment is documented. Punitive damages, if applicable, can further increase the total recovery.
FAQ 2: What is the difference between the FreeStyle Libre 3 class action and an individual personal injury lawsuit?
The class action filed in Alameda County in February 2026 primarily addresses economic harms and consumer protection claims on behalf of large numbers of purchasers. Individual personal injury lawsuits are filed by people who suffered serious physical harm — seizures, cardiac events, hospitalizations, or death — and allow plaintiffs to pursue full compensatory and punitive damages specific to their injuries. Individuals with serious injuries should not rely on the class action to fully compensate them and should consult with an attorney about filing an independent claim.
FAQ 3: Can I sue Abbott if my child was injured by a defective FreeStyle Libre 3 sensor?
Yes. The FreeStyle Libre 3 and Libre 3 Plus sensors are cleared for use in patients as young as 2 years old, and children are expressly within the scope of affected users. If your child was harmed by an inaccurate reading — through incorrect insulin dosing, a hypoglycemic episode, or any other injury — you may file a personal injury claim on behalf of your minor child. Statutes of limitations for minors are typically tolled until the child reaches the age of majority, though you should consult an attorney immediately to preserve critical evidence.
FAQ 4: Does the FDA recall and warning letter help my individual lawsuit?
Significantly, yes. The November 2025 recall establishes that Abbott itself acknowledged the devices were defective. The January 2026 FDA warning letter goes further, documenting that Abbott violated quality system regulations by releasing devices without adequately testing accuracy after final assembly and sterilization. These regulatory findings are admissible as evidence in product liability litigation and substantially strengthen individual claims by helping to establish both the existence of a defect and Abbott’s knowledge or recklessness regarding that defect — factors that are also relevant to punitive damage claims.
FAQ 5: What evidence should I gather to support a FreeStyle Libre 3 injury claim?
To build the strongest possible claim in the FreeStyle Libre 3 lawsuit glucose sensor defect litigation, preserve and collect the following: (1) the physical sensor, packaging, and any lot numbers if still available; (2) all medical records from emergency visits, hospitalizations, or follow-up treatment related to the injury; (3) records showing the glucose readings displayed by the sensor, including any app screenshots or downloaded data from the LibreView cloud platform; (4) contemporaneous blood glucose readings from fingerstick tests or other devices that confirm the sensor inaccuracy; (5) pharmacy or insurance records showing your purchase and use of the recalled sensors; and (6) any correspondence with Abbott or your healthcare provider about the device or the recall.
Legal disclaimer: The information on this page is provided for general educational purposes only and does not constitute legal advice; consult a licensed attorney in your jurisdiction regarding the specific facts of your situation.
Related reading: Commercial Truck ADAS Technology Provider Liability: Settlement Calculator For AI Driver Monitoring & Automatic Braking Defects (2026)
James Mitchell is a personal injury legal researcher with over a decade of experience analyzing settlement data and compensation trends across the United States. He has studied thousands of personal injury cases to help injury victims understand their legal rights and the potential value of their claims. James is not an attorney and the information he provides is for
educational purposes only.